ziprasidone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2865	146939-27-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ziprasidone zaprasidone ziprasidone hydrochloride ziprasidone mesylate geodon ziprasidone HCl ziprasidone mesilate	a benzisothiazoylpiperazine derivative; has combined dopamine and serotonin receptor antagonist activity; structurally related to tiospirone Molecular weight: 412.94 Formula: C21H21ClN4OS CLOGP: 4.21 LIPINSKI: 0 HAC: 5 HDO: 1 TPSA: 48.47 ALOGS: -4.76 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ziprasidone
zaprasidone
ziprasidone hydrochloride
ziprasidone mesylate
geodon
ziprasidone HCl
ziprasidone mesilate

a benzisothiazoylpiperazine derivative; has combined dopamine and serotonin receptor antagonist activity; structurally related to tiospirone

Molecular weight: 412.94
Formula: C21H21ClN4OS
CLOGP: 4.21
LIPINSKI: 0
HAC: 5
HDO: 1
TPSA: 48.47
ALOGS: -4.76
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
80	mg	O
40	mg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.00 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	6.36 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	60 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	5.10 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.00 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	3.10 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Feb. 5, 2001	FDA	PFIZER

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Tardive dyskinesia	1011.60	36.39	184	2695	1520	2353686
Dystonia	743.22	36.39	148	2731	2046	2353160
Completed suicide	683.55	36.39	216	2663	20818	2334388
Neuroleptic malignant syndrome	536.55	36.39	112	2767	1968	2353238
Extrapyramidal disorder	494.75	36.39	107	2772	2240	2352966
Sedation	482.98	36.39	112	2767	3250	2351956
Electrocardiogram QT prolonged	443.69	36.39	124	2755	7690	2347516
Dyskinesia	428.71	36.39	109	2770	4680	2350526
Akathisia	345.06	36.39	75	2804	1599	2353607
Tremor	339.72	36.39	128	2751	20533	2334673
Drug hypersensitivity	274.27	36.39	140	2739	46503	2308703
Agitation	262.34	36.39	90	2789	10961	2344245
Anxiety	253.99	36.39	115	2764	29244	2325962
Weight increased	253.53	36.39	106	2773	22231	2332975
Suicide attempt	245.05	36.39	86	2793	11196	2344010
Drug ineffective	243.99	36.39	171	2708	101453	2253753
Cardio-respiratory arrest	234.69	36.39	79	2800	9067	2346139
Somnolence	231.90	36.39	101	2778	23384	2331822
Blood prolactin abnormal	221.74	36.39	34	2845	76	2355130
Mania	220.20	36.39	56	2823	2384	2352822
Parkinsonism	214.94	36.39	50	2829	1455	2353751
Depression	211.34	36.39	100	2779	28032	2327174
Anosognosia	210.35	36.39	31	2848	46	2355160
Psychotic disorder	210.12	36.39	62	2817	4617	2350589
Sexual dysfunction	203.62	36.39	37	2842	295	2354911
Insomnia	170.32	36.39	84	2795	25703	2329503
Toxicity to various agents	159.68	36.39	87	2792	32667	2322539
Disturbance in social behaviour	154.26	36.39	27	2852	169	2355037
Suicidal ideation	154.18	36.39	61	2818	11026	2344180
Torsade de pointes	151.80	36.39	41	2838	2205	2353001
Cardiac arrest	146.36	36.39	64	2815	14866	2340340
Metabolic disorder	145.88	36.39	31	2848	587	2354619
Respiratory arrest	137.36	36.39	48	2831	6130	2349076
Condition aggravated	131.46	36.39	76	2803	31903	2323303
Hallucination	124.40	36.39	48	2831	8100	2347106
Paranoia	121.69	36.39	34	2845	2073	2353133
Seizure	116.32	36.39	64	2815	24402	2330804
Dysphagia	116.12	36.39	52	2827	12753	2342453
Delusion	113.24	36.39	32	2847	2033	2353173
Personality change	112.02	36.39	27	2852	914	2354292
Loss of consciousness	111.55	36.39	57	2822	18710	2336496
Swollen tongue	109.17	36.39	39	2840	5304	2349902
Overdose	108.38	36.39	57	2822	19850	2335356
Galactorrhoea	108.22	36.39	28	2851	1271	2353935
Restlessness	107.36	36.39	37	2842	4526	2350680
Feeling abnormal	104.73	36.39	59	2820	23522	2331684
Blood prolactin increased	103.65	36.39	26	2853	1041	2354165
Syncope	102.44	36.39	52	2827	16823	2338383
Musculoskeletal stiffness	96.13	36.39	45	2834	12202	2343004
Blood glucose increased	95.97	36.39	45	2834	12245	2342961
Muscle twitching	91.44	36.39	29	2850	2736	2352470
Abnormal behaviour	86.96	36.39	32	2847	4728	2350478
Hallucination, auditory	85.11	36.39	26	2853	2166	2353040
Dizziness	83.60	36.39	73	2806	58592	2296614
Schizophrenia	83.36	36.39	23	2856	1336	2353870
Aggression	83.12	36.39	31	2848	4755	2350451
Hyperprolactinaemia	82.26	36.39	20	2859	702	2354504
Muscle rigidity	80.93	36.39	24	2855	1807	2353399
Gait disturbance	80.50	36.39	49	2830	22496	2332710
Coma	76.40	36.39	35	2844	9021	2346185
Withdrawal syndrome	74.38	36.39	26	2853	3311	2351895
Dyspnoea	74.24	36.39	78	2801	78655	2276551
Mental disorder	73.41	36.39	27	2852	3980	2351226
Orthostatic hypertension	71.32	36.39	12	2867	57	2355149
Insurance issue	70.86	36.39	16	2863	404	2354802
Rash	70.86	36.39	67	2812	59491	2295715
Catatonia	69.22	36.39	18	2861	832	2354374
Weight decreased	67.87	36.39	48	2831	28323	2326883
Oculogyric crisis	67.85	36.39	15	2864	343	2354863
Cardiometabolic syndrome	67.71	36.39	14	2865	230	2354976
Confusional state	67.22	36.39	45	2834	24299	2330907
Psychomotor hyperactivity	67.03	36.39	21	2858	1901	2353305
Bipolar disorder	65.84	36.39	19	2860	1299	2353907
Serotonin syndrome	65.39	36.39	24	2855	3516	2351690
Tachycardia	64.60	36.39	38	2841	16371	2338835
Nausea	64.05	36.39	86	2793	112103	2243103
Drug intolerance	62.64	36.39	35	2844	13682	2341524
Intentional overdose	60.33	36.39	32	2847	11289	2343917
Blood creatine phosphokinase increased	60.08	36.39	25	2854	5111	2350095
Thinking abnormal	58.57	36.39	19	2860	1923	2353283
Intentional product misuse	56.80	36.39	29	2850	9460	2345746
Asthenia	56.14	36.39	53	2826	46873	2308333
Fatigue	56.07	36.39	70	2809	84803	2270403
Vomiting	55.38	36.39	64	2815	71538	2283668
Vision blurred	55.19	36.39	33	2846	14635	2340571
Dysarthria	55.16	36.39	25	2854	6277	2348929
Trismus	54.42	36.39	15	2864	867	2354339
Drug interaction	53.30	36.39	42	2837	29121	2326085
Drug withdrawal syndrome	53.26	36.39	25	2854	6796	2348410
Muscle spasms	52.72	36.39	37	2842	21529	2333677
Treatment noncompliance	51.76	36.39	23	2856	5511	2349695
Diabetes mellitus	51.02	36.39	25	2854	7470	2347736
Visual impairment	50.96	36.39	29	2850	11726	2343480
Ventricular tachycardia	50.42	36.39	19	2860	2992	2352214
Dry mouth	48.74	36.39	25	2854	8228	2346978
Irritability	48.47	36.39	23	2856	6404	2348802
Movement disorder	47.92	36.39	18	2861	2810	2352396
Bruxism	47.42	36.39	13	2866	736	2354470
Lethargy	47.41	36.39	25	2854	8705	2346501
Product substitution issue	47.19	36.39	21	2858	5048	2350158
Muscle tightness	46.92	36.39	16	2863	1889	2353317
Torticollis	46.03	36.39	11	2868	358	2354848
Affective disorder	45.76	36.39	13	2866	839	2354367
Cogwheel rigidity	44.97	36.39	10	2869	235	2354971
Depressed level of consciousness	44.80	36.39	23	2856	7581	2347625
Rhabdomyolysis	44.55	36.39	22	2857	6682	2348524
Poisoning	44.35	36.39	17	2862	2803	2352403
Rabbit syndrome	43.85	36.39	8	2871	65	2355141
Adverse drug reaction	42.95	36.39	23	2856	8260	2346946
Generalised tonic-clonic seizure	42.89	36.39	20	2859	5352	2349854
Death	42.64	36.39	60	2819	81408	2273798
Exposure via ingestion	42.22	36.39	12	2867	776	2354430
Obesity	42.17	36.39	14	2865	1522	2353684
Mental status changes	42.16	36.39	20	2859	5562	2349644
Panic attack	42.06	36.39	18	2861	3938	2351268
Hypomania	41.93	36.39	12	2867	795	2354411
Fall	41.30	36.39	45	2834	47054	2308152
Photophobia	40.35	36.39	15	2864	2274	2352932
Appetite disorder	40.07	36.39	11	2868	626	2354580
Disorientation	39.65	36.39	20	2859	6352	2348854
Drug dependence	39.61	36.39	16	2863	3029	2352177
Incorrect dose administered	39.56	36.39	23	2856	9672	2345534
Obsessive-compulsive disorder	39.55	36.39	11	2868	657	2354549
Constipation	39.17	36.39	31	2848	21598	2333608
Sjogren's syndrome	39.15	36.39	12	2867	1009	2354197
Tenderness	39.13	36.39	14	2865	1904	2353302
Skin warm	39.07	36.39	11	2868	687	2354519
Tongue disorder	38.02	36.39	12	2867	1111	2354095
Myalgia	37.10	36.39	31	2848	23302	2331904
Haemorrhagic diathesis	37.08	36.39	10	2869	532	2354674
Restless legs syndrome	36.82	36.39	14	2865	2257	2352949
Speech disorder	36.48	36.39	19	2860	6445	2348761
Sleep disorder	36.41	36.39	19	2860	6470	2348736

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dystonia	487.01	41.40	106	1979	1908	1742788
Neuroleptic malignant syndrome	434.72	41.40	105	1980	3043	1741653
Completed suicide	344.08	41.40	127	1958	16185	1728511
Extrapyramidal disorder	341.78	41.40	82	2003	2295	1742401
Tardive dyskinesia	331.01	41.40	70	2015	1082	1743614
Dyskinesia	284.45	41.40	78	2007	3741	1740955
Agitation	281.36	41.40	99	1986	10927	1733769
Electrocardiogram QT prolonged	247.16	41.40	76	2009	5469	1739227
Sedation	227.69	41.40	64	2021	3353	1741343
Anxiety	227.52	41.40	93	1992	15434	1729262
Somnolence	217.41	41.40	92	1993	16647	1728049
Drug ineffective	211.09	41.40	140	1945	63661	1681035
Psychotic disorder	207.11	41.40	65	2020	4991	1739705
Aggression	199.51	41.40	71	2014	8044	1736652
Akathisia	196.69	41.40	47	2038	1281	1743415
Priapism	192.14	41.40	47	2038	1417	1743279
Weight increased	190.27	41.40	75	2010	11282	1733414
Insomnia	177.00	41.40	79	2006	16197	1728499
Swollen tongue	157.36	41.40	46	2039	2762	1741934
Suicidal ideation	152.19	41.40	59	2026	8459	1736237
Tremor	137.03	41.40	62	2023	13069	1731627
Mania	124.13	41.40	36	2049	2097	1742599
Toxicity to various agents	123.06	41.40	75	2010	29066	1715630
Bruxism	118.49	41.40	24	2061	293	1744403
Homicidal ideation	117.96	41.40	27	2058	604	1744092
Hallucination	112.65	41.40	47	2038	8123	1736573
Cardiac arrest	110.87	41.40	57	2028	15873	1728823
Catatonia	108.88	41.40	27	2058	858	1743838
Speech disorder	108.54	41.40	39	2046	4509	1740187
Drug hypersensitivity	101.96	41.40	53	2032	15082	1729614
Decreased eye contact	99.62	41.40	16	2069	42	1744654
Blood creatine phosphokinase increased	99.22	41.40	44	2041	8812	1735884
Oppositional defiant disorder	96.61	41.40	16	2069	54	1744642
Paranoia	93.12	41.40	29	2056	2152	1742544
Psychomotor hyperactivity	92.84	41.40	28	2057	1865	1742831
Parkinsonism	88.08	41.40	25	2060	1344	1743352
Seizure	87.08	41.40	53	2032	20388	1724308
Depression	86.18	41.40	49	2036	16620	1728076
Hallucination, auditory	85.58	41.40	27	2058	2090	1742606
Condition aggravated	85.41	41.40	53	2032	21097	1723599
Anosognosia	83.07	41.40	14	2071	54	1744642
Oculogyric crisis	81.15	41.40	18	2067	347	1744349
Muscle rigidity	80.68	41.40	25	2060	1823	1742873
Suicide attempt	80.48	41.40	36	2049	7345	1737351
Euphoric mood	80.38	41.40	21	2064	824	1743872
Serotonin syndrome	78.28	41.40	27	2058	2761	1741935
Feeling abnormal	77.70	41.40	40	2045	11126	1733570
Musculoskeletal stiffness	74.90	41.40	32	2053	5844	1738852
Sydenham's chorea	72.50	41.40	10	2075	3	1744693
Hyperhidrosis	70.71	41.40	39	2046	12449	1732247
Restlessness	70.22	41.40	28	2057	4293	1740403
Drug interaction	69.71	41.40	52	2033	27906	1716790
Crying	68.81	41.40	21	2064	1454	1743242
Dizziness	68.55	41.40	56	2029	34305	1710391
Coordination abnormal	68.50	41.40	21	2064	1476	1743220
Trismus	68.34	41.40	17	2068	546	1744150
Delusion	68.07	41.40	23	2062	2208	1742488
Cardio-respiratory arrest	66.68	41.40	34	2051	9259	1735437
Bipolar disorder	63.23	41.40	17	2068	745	1743951
Respiratory arrest	62.09	41.40	28	2057	5811	1738885
Obsessive-compulsive disorder	61.84	41.40	17	2068	811	1743885
Tachycardia	59.54	41.40	35	2050	12593	1732103
Choreoathetosis	58.16	41.40	12	2073	161	1744535
Schizophrenia	58.13	41.40	20	2065	2026	1742670
Sleep disorder	58.01	41.40	24	2061	4039	1740657
Blood prolactin abnormal	57.90	41.40	10	2075	46	1744650
Irritability	57.14	41.40	26	2059	5506	1739190
Antipsychotic drug level below therapeutic	57.10	41.40	12	2073	177	1744519
Nervousness	56.47	41.40	20	2065	2207	1742489
Therapeutic product effect variable	55.32	41.40	11	2074	121	1744575
Disinhibition	55.15	41.40	13	2072	331	1744365
Thinking abnormal	54.11	41.40	17	2068	1295	1743401
Depressed mood	54.09	41.40	21	2064	2995	1741701
Rhabdomyolysis	52.95	41.40	31	2054	11059	1733637
Treatment noncompliance	52.31	41.40	24	2061	5177	1739519
Loss of consciousness	51.79	41.40	34	2051	14841	1729855
Abnormal behaviour	50.75	41.40	25	2060	6317	1738379
Overdose	50.56	41.40	35	2050	16666	1728030
Increased appetite	50.33	41.40	15	2070	956	1743740
Vision blurred	49.55	41.40	27	2058	8396	1736300
Anger	49.36	41.40	19	2066	2647	1742049
Blood glucose increased	48.98	41.40	29	2056	10555	1734141
Lethargy	47.80	41.40	25	2060	7159	1737537
Torticollis	46.22	41.40	11	2074	292	1744404
Nausea	46.15	41.40	54	2031	51142	1693554
Gynaecomastia	46.02	41.40	17	2068	2115	1742581
Myopathy toxic	44.39	41.40	9	2076	110	1744586
Disturbance in social behaviour	44.25	41.40	10	2075	210	1744486
Dyspnoea	43.77	41.40	53	2032	52006	1692690
Fatigue	43.18	41.40	52	2033	50729	1693967
Erectile dysfunction	42.87	41.40	20	2065	4477	1740219
Dysphagia	42.24	41.40	26	2059	10142	1734554

Pharmacologic Action:

Source	Code	Description
ATC	N05AE04	NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Indole derivatives
FDA EPC	N0000175430	Atypical Antipsychotic
MeSH PA	D014150	Antipsychotic Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018492	Dopamine Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D018490	Serotonin Agents
MeSH PA	D012702	Serotonin Antagonists
CHEBI has role	CHEBI:35471	psychotropic drug
CHEBI has role	CHEBI:37956	histamine antagonist
CHEBI has role	CHEBI:48876	muscarinic antagonist
CHEBI has role	CHEBI:48279	serotonergic antagonist
CHEBI has role	CHEBI:48561	dopaminergic antagonist
CHEBI has role	CHEBI:35476	antipsychotic agent
MeSH PA	D014149	Tranquilizing Agents

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Mixed bipolar I disorder	indication	16506000	DOID:3312
Schizophrenia	indication	58214004	DOID:5419
Bipolar disorder in remission	indication	85248005
Bipolar affective disorder, current episode manic	indication	191618007
Agitation associated with Schizophrenia	indication
Bipolar affective disorder, current episode depression	off-label use	191627008	DOID:3312
Depression Treatment Adjunct	off-label use
Tachyarrhythmia	contraindication	6285003
Suicidal thoughts	contraindication	6471006
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464
Senile dementia	contraindication	15662003
Agranulocytosis	contraindication	17182001	DOID:12987
Myocardial infarction	contraindication	22298006	DOID:5844
Hypovolemia	contraindication	28560003
Orthostatic hypotension	contraindication	28651003
Torsades de pointes	contraindication	31722008
Dehydration	contraindication	34095006
Dysphagia	contraindication	40739000
Hypokalemia	contraindication	43339004
Conduction disorder of the heart	contraindication	44808001
Bradycardia	contraindication	48867003
Hyperlipidemia	contraindication	55822004	DOID:1168
Hepatic failure	contraindication	59927004
Cerebrovascular disease	contraindication	62914000	DOID:6713
Diabetes mellitus	contraindication	73211009	DOID:9351
Extrapyramidal disease	contraindication	76349003
Hyperglycemia	contraindication	80394007	DOID:4195
Heart failure	contraindication	84114007	DOID:6000
Epilepsy	contraindication	84757009	DOID:1826
Leukopenia	contraindication	84828003	DOID:615
Kidney disease	contraindication	90708001	DOID:557
Tardive dyskinesia	contraindication	102449007
Prolonged QT interval	contraindication	111975006
Hypomagnesemia	contraindication	190855004
Decompensated cardiac failure	contraindication	195111005
Metabolic syndrome X	contraindication	237602007	DOID:14221
Neutropenic disorder	contraindication	303011007	DOID:1227
Severe diarrhea	contraindication	409587002
Breastfeeding (mother)	contraindication	413712001
Myocardial ischemia	contraindication	414795007	DOID:3393
Obesity	contraindication	414916001	DOID:9970
Acquired torsion dystonia	contraindication	433493000
Congenital long QT syndrome	contraindication	442917000
Carcinoma of female breast	contraindication	447782002

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.26	acidic
pKa2	7.35	Basic
pKa3	0.27	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN	ANTAGONIST	Ki	9.40	WOMBAT-PK	CHEMBL
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	ANTAGONIST	Ki	8.32	WOMBAT-PK	CHEMBL
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN		Ki	5.59	PDSP
5-hydroxytryptamine receptor 5A	GPCR	P47898	5HT5A_HUMAN		Ki	6.54	PDSP
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	7.56	PDSP
Alpha-1B adrenergic receptor	GPCR	P35368	ADA1B_HUMAN		Ki	8.05	PDSP
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		Ki	5.46	PDSP
D(1B) dopamine receptor	GPCR	P21918	DRD5_HUMAN		Ki	6.82	PDSP
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	5	PDSP
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	7.11	PDSP
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	7.32	PDSP
5-hydroxytryptamine receptor 1B	GPCR	P28222	5HT1B_HUMAN	AGONIST	Ki	8.30	IUPHAR
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN	ANTAGONIST	Ki	8.89	WOMBAT-PK
5-hydroxytryptamine receptor 1E	GPCR	P28566	5HT1E_HUMAN		Ki	6.44	WOMBAT-PK
5-hydroxytryptamine receptor 3A	Ion channel	P46098	5HT3A_HUMAN		Ki	6.40	WOMBAT-PK
5-hydroxytryptamine receptor 1D	GPCR	P28221	5HT1D_HUMAN		Ki	8.70	WOMBAT-PK
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	6.55	WOMBAT-PK
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	7.33	WOMBAT-PK
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN		Ki	8	WOMBAT-PK
5-hydroxytryptamine receptor 7	GPCR	P34969	5HT7R_HUMAN		Ki	8.30	WOMBAT-PK
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	7.22	WOMBAT-PK
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		EC50	8.47	WOMBAT-PK
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		IC50	7	WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	6.92	WOMBAT-PK
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.30	WOMBAT-PK
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	7.36	PDSP
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	5.80	PDSP
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	5.80	PDSP
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	5.52	PDSP
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN		Ki	5.30	PDSP
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	8.02	CHEMBL
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN				WOMBAT-PK
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN	ANTAGONIST	Ki	7.30	WOMBAT-PK
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN	ANTAGONIST	Ki	8.14	WOMBAT-PK
Transporter	Transporter		Q63380_RAT		Ki	7.32	CHEMBL
Histamine H1 receptor	GPCR		HRH1_RAT		IC50	6.82	CHEMBL
Adrenergic receptor alpha-1	GPCR		ADA1A_RAT ADA1B_RAT ADA1D_RAT		Ki	7.96	CHEMBL
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		Ki	9.30	CHEMBL
D(2) dopamine receptor	GPCR		DRD2_RAT		Ki	8.32	CHEMBL
5-hydroxytryptamine receptor 2A	GPCR		5HT2A_RAT		Ki	9.38	CHEMBL
Histamine H1 receptor	GPCR		HRH1_CAVPO		Ki	7.80	CHEMBL

External reference:

ID	Source
4021249	VUID
N0000148690	NUI
C0380393	UMLSCUI
D02100	KEGG_DRUG
216X081ORU	UNII
138982-67-9	SECONDARY_CAS_RN
7155	INN_ID
373389002	SNOMEDCT_US
4021249	VANDF
009104	NDDF
d04747	MMSL
115698	RXNORM
409356003	SNOMEDCT_US
CHEMBL708	ChEMBL_ID
DB00246	DRUGBANK_ID
CHEMBL1712	ChEMBL_ID
CHEBI:10119	CHEBI
CHEMBL1200997	ChEMBL_ID
CHEMBL1375743	ChEMBL_ID
CHEMBL3989833	ChEMBL_ID
60854	PUBCHEM_CID
59	IUPHAR_LIGAND_ID
C092292	MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Geodon	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0052	CAPSULE	20 mg	ORAL	NDA	20 sections
Geodon	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0054	CAPSULE	40 mg	ORAL	NDA	20 sections
Geodon	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0056	CAPSULE	60 mg	ORAL	NDA	20 sections
Geodon	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0058	CAPSULE	80 mg	ORAL	NDA	20 sections
Geodon	HUMAN PRESCRIPTION DRUG LABEL	1	0049-1203	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAMUSCULAR	NDA	19 sections
Geodon	HUMAN PRESCRIPTION DRUG LABEL	1	0049-3920	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAMUSCULAR	NDA	20 sections
Geodon	HUMAN PRESCRIPTION DRUG LABEL	1	0049-3960	CAPSULE	20 mg	ORAL	NDA	20 sections
Geodon	HUMAN PRESCRIPTION DRUG LABEL	1	0049-3980	CAPSULE	60 mg	ORAL	NDA	20 sections
Geodon	HUMAN PRESCRIPTION DRUG LABEL	1	0049-3990	CAPSULE	80 mg	ORAL	NDA	20 sections
ziprasidone hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-7703	CAPSULE	80 mg	ORAL	ANDA	20 sections
ziprasidone hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-2164	CAPSULE	20 mg	ORAL	ANDA	18 sections
ziprasidone hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-2166	CAPSULE	40 mg	ORAL	ANDA	18 sections
ziprasidone hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-2167	CAPSULE	60 mg	ORAL	ANDA	18 sections
ziprasidone hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-2168	CAPSULE	80 mg	ORAL	ANDA	18 sections
Ziprasidone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6269	CAPSULE	20 mg	ORAL	ANDA	19 sections
Ziprasidone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6270	CAPSULE	40 mg	ORAL	ANDA	19 sections
Ziprasidone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6271	CAPSULE	60 mg	ORAL	ANDA	19 sections
Ziprasidone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6272	CAPSULE	80 mg	ORAL	ANDA	19 sections
GEODON	HUMAN PRESCRIPTION DRUG LABEL	1	16590-895	CAPSULE	20 mg	ORAL	NDA	20 sections
ziprasidone hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16714-835	CAPSULE	20 mg	ORAL	ANDA	19 sections
ziprasidone hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16714-836	CAPSULE	40 mg	ORAL	ANDA	19 sections
ziprasidone hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16714-837	CAPSULE	60 mg	ORAL	ANDA	19 sections
ziprasidone hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16714-838	CAPSULE	80 mg	ORAL	ANDA	19 sections
Geodon	HUMAN PRESCRIPTION DRUG LABEL	1	21695-060	CAPSULE	20 mg	ORAL	NDA	20 sections
Geodon	HUMAN PRESCRIPTION DRUG LABEL	1	21695-061	CAPSULE	40 mg	ORAL	NDA	20 sections
Geodon	HUMAN PRESCRIPTION DRUG LABEL	1	21695-062	CAPSULE	60 mg	ORAL	NDA	20 sections
Geodon	HUMAN PRESCRIPTION DRUG LABEL	1	21695-063	CAPSULE	80 mg	ORAL	NDA	20 sections
Ziprasidone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	33342-144	CAPSULE	20 mg	ORAL	ANDA	20 sections
Ziprasidone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	33342-145	CAPSULE	40 mg	ORAL	ANDA	20 sections
Ziprasidone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	33342-146	CAPSULE	60 mg	ORAL	ANDA	20 sections